In-vitro assessment of lomefloxacin (SC-47111)--a new quinolone derivative.
The activity of lomefloxacin (SC-47111) was studied in vitro against 500 clinical isolates. Comparison was made with enoxacin and ciprofloxacin. Lomefloxacin was comparable in activity to enoxacin, but less active than ciprofloxacin. Most Gram-negative bacilli were susceptible, including several multi-resistant strains. Pseudomonas aeruginosa showed variable susceptibility. Streptococci, including Streptococcus pneumoniae, were generally the least susceptible organisms.
Finch
R
R
Department of Microbial Diseases, City Hospital, Nottingham, UK.
Martin
J
J
Pilkington
R
R
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002939:Ciprofloxacin / Q000494:pharmacology; D015365:Enoxacin / Q000494:pharmacology; D024841:Fluoroquinolones; D008826:Microbial Sensitivity Tests; D015363:Quinolones
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D015363:Quinolones; D015365:Enoxacin; D002939:Ciprofloxacin; C053091:lomefloxacin